Combination Lipid Therapy in Type 2 Diabetes
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of triglycerides with the proliferator activated receptor-alpha agonist fenofibrate failed to reduce ASCVD events in 2 separate trials in persons with T2D: (Fenofibrate Intervention and Event Lowering in Diabetes [FIELD]377 and ACCORD-Lipid),367 although the mean baseline triglyceride levels were 153 mg/dL in FIELD377 and 162 mg/dL in ACCORD-Lipid.367”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [377]
In the citing paper
“Yet, subgroup analyses have strongly suggested that patients with high triglyceride and low high-density lipoprotein (HDL) cholesterol levels might derive substantial clinical benefit from decreased triglyceride levels, particularly if they have concomitant type 2 diabetes. 7,8”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [7]
In the citing paper
“the significant reduction of CV event risk was shown for each test, particularly in the post-hoc analysis of the subclasses of patients with or without statin who had atherogenic dyslipidemia (high serum TG and low HDL-C levels) [12].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [12]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., Wexler, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 921
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Research works printed but not linked: 2
- 10.1001/jama.2009.1619 · DOI · Paper page
- 10.1056/NEJMoa1001282 · DOI · Paper page
Cited by
Items 101–200 of 244
Manoria, P. C., Chopra, H. K., Parashar, S.-R., Dutta, A. L., Pinto, B., Mullasari, A., & Prajapati, S. (2013) · Indian Heart Journal · doi:10.1016/j.ihj.2013.10.015 · Cited by 33
Treatment of Hypertriglyceridemia: a Review of Current Options
Vrablík, M., & Češka, R. (2015) · Physiological Research · doi:10.33549/physiolres.933199 · Cited by 28
Beyond statins: what to expect from add-on lipid regulating therapy?
Laufs, U., Weintraub, W., & Packard, C. J. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht213 · Cited by 23
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.012 · Cited by 24
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.007 · Cited by 24
Consensus statement on the management of dyslipidaemias in adults
Béliard, S., Bonnet, F., Bouhanick, B., Bruckert, É., Cariou, B., Charrière, S., Durlach, V., Moulin, P., Valéro, R., & Vergès, B. L. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.07.033 · Cited by 23
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk
Graham, I. M., Shear, C. L., de Graeff, P., Boulton, C., Catapano, A. L., Stough, W. G., Carlsson, S. C., Backer, G. D., Emmerich, J., Greenfeder, S. A., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvx031 · Cited by 22
Towards more specific treatment for diabetic dyslipidemia
Rodriguez, V., Newman, J. D., & Schwartzbard, A. Z. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000528 · Cited by 23
Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians
Hermans, M. P., & Fruchart, J. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311413952 · Cited by 20
Do Persons with Diabetes Benefit from Combination Statin and Fibrate Therapy?
Rosenblit, P. D. (2012) · Current Cardiology Reports · doi:10.1007/s11886-011-0237-7 · Cited by 22
Tonkin, A. M., & Byrnes, A. (2014) · F1000Prime Reports · doi:10.12703/p6-17 · Cited by 32
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
Reyes‐Soffer, G., Rondon-Clavo, C., & Ginsberg, H. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.563506 · Cited by 19
Fruchart, J., Hermans, M. P., & Fruchart‐Najib, J. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00860-w · Cited by 19
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.07.003 · Cited by 20
“significant MACE reduction in diabetes patients with atherogenic dyslipidaemia [196].”
BackgroundTriglycerides and Cardiovascular Outcomes—Can We REDUCE-IT ?
Pradhan, A. K., Bhandari, M., Vishwakarma, P., & Sethi, R. (2020) · International Journal of Angiology · doi:10.1055/s-0040-1701639 · Cited by 19
Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve, V., Millán, J., Blanco, A., Blasco, M., Díaz-Díaz, J. L., Rodríguez, Á. D., Mangas, A., Pascual, V., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.02.001 · Cited by 29
Lessons from PROMINENT and prospects for pemafibrate
Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02305-z · Cited by 16
SPPARM alpha: the Lazarus effect
Fruchart, J., & Santos, R. D. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000640 · Cited by 19
Statin Combination Therapy and Cardiovascular Risk Reduction
Toth, P. P., Farnier, M., Tomassini, J. E., Foody, J. M., & Tershakovec, A. M. (2016) · Future Cardiology · doi:10.2217/fca-2015-0011 · Cited by 17
Combination Lipid Therapy in Type 2 Diabetes
Clearfield, M. B. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0139-y · Cited by 16
Al-Hashmi, K., Al-Zakwani, I. S., Almahmeed, W. A., Arafah, M., Al-Hinai, A. T., Shehab, A. M., Tamimi, O. A., Alawadhi, M., Herz, S. A., Anazi, F. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.021 · Cited by 17
Davidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Setze, C. M., Carlson, D. M., & Stolzenbach, J. C. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6395-z · Cited by 15
Safety review of combination drugs for hyperlipidemia
Farnier, M. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.540237 · Cited by 15
Diabetes Mellitus and the Cardiovascular System
Kolakalapudi, P., & Omar, B. A. (2015) · Journal of Endocrinology and Metabolism · doi:10.14740/jem324e · Cited by 17
Do triglyceride-lowering drugs decrease risk of cardiovascular disease?
Maki, K. C., & Dicklin, M. R. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000424 · Cited by 14
The Use of Fibric Acid Derivatives in Cardiovascular Prevention
Khoury, N., & Goldberg, A. C. (2011) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-011-0128-7 · Cited by 16
Risk prediction with triglycerides in patients with stable coronary disease on statin treatment
Werner, C., Filmer, A., Fritsch, M., Groenewold, S., Gräber, S., Böhm, M., & Laufs, U. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0740-0 · Cited by 13
“Post hoc analyzes of studies testing lipid lowering on top of statin treatment raise the hypothesis that subgroups of patients with high triglycerides may benefit from additional lipid regulation [49].”
BackgroundFarnier, M., Ducobu, J., & Bryniarski, L. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.626398 · Cited by 14
Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol
Stefanutti, C., Labbadia, G., & Athyros, V. G. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140620120130 · Cited by 15
Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos
Hernández‐Mijares, A., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.007 · Cited by 17
Roussel, R., Chaignot, C., Weill, A., Travert, F., Hansel, B., Marre, M., Ricordeau, P., Alla, F., & Allemand, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137733 · Cited by 13
Diabeteses dyslipidaemia és atherosclerosis
Márk, L., & Dani, G. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30441 · Cited by 18
Research Progress of Hypertriglyceridemia and Coronary Heart Disease
Ji, Y., & Bai, C. (2018) · Heart and Mind · doi:10.4103/hm.hm_2_19 · Cited by 14
Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management
Núñez-Cortés, J. M., Pedro‐Botet, J., Brea-Hernando, Á., Rodríguez, Á. D., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Pintó, X., & Simó, R. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.06.011 · Cited by 13
Farnier, M., Marcereuil, D., Niet, S. D., Ducobu, J., Steinmetz, A., Retterstøl, K., Bryniarski, L., Császár, A., & Vanderbist, F. (2012) · Clinical Drug Investigation · doi:10.2165/11630820-000000000-00000 · Cited by 13
Dislipidemia y riesgo vascular. Una revisión basada en nuevas evidencias
Pallarés‐Carratalá, V., Fuster, V. P., & Rocati, D. V. G. (2015) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.10.015 · Cited by 31
Dislipidemia aterogénica y riesgo residual. Estado de la cuestión en 2014
Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2014) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.09.004 · Cited by 21
Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction
Zambon, A., Pirillo, A., Zambon, S., Norata, G. D., & Catapano, A. L. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00893-1 · Cited by 12
Remnant cholesterol, vascular risk, and prevention of atherosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve-Luque, V., & Millán, J. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.005 · Cited by 18
Volpe, M., Volpe, R., Gallo, G., Presta, V., Tocci, G., Folco, E., Peracino, A. P., Tremoli, E., & Trimarco, B. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0211-6 · Cited by 13
Hyperlipidemia and cardiovascular disease: triglycerides – a revival of cardiovascular risk factor?
Nofer, J. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328348a539 · Cited by 11
Iglesias, O. L., Marcos, J. S., Cortés, V., Luque, A., Gaillemin, B. C., Delgado, A. V., Martínez, A. M., & López, J. L. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2011.11.004 · Cited by 11
Residual Vascular Risk in T2DM: The Next Frontier
Michel, P., Sylvie, A., & Michel, F. (2011) · InTech eBooks · doi:10.5772/22716 · Cited by 10
Lipid-lowering Therapies in Myositis
Mizus, M. C., & Tiniakou, E. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00942-3 · Cited by 11
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 11
High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?
von Eckardstein, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_536 · Cited by 13
Jinnouchi, H., Morita, K., Tanaka, T., Kajiwara, A., Kawata, Y., Oniki, K., Saruwatari, J., Nakagawa, K., Otake, K., Ogata, Y., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0212-5 · Cited by 10
Lipid Management in Diabetes with a Focus on Emerging Therapies
Hoe, E., & Hegele, R. A. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.012 · Cited by 10
Not all fibrates are made equal: Learning from biology and clinical trials
Zambon, A., Staels, B., Farnier, M., Vrablík, M., & Catapano, A. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120555 · Cited by 8
Brea, Á., Pintó, X., Ascaso, J. F., Blasco, M., Rodríguez, Á. D., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Millán, J., & Pedro‐Botet, J. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.06.002 · Cited by 9
Velidakis, N., Stachteas, P., Gkougkoudi, E., Papadopoulos, C. E., & Kadoglou, N. P. E. (2024) · Pharmaceuticals · doi:10.3390/ph17050568 · Cited by 9
de Expertos, G. D. T. D. D. A. D. L. S. E. D. A. Y. G. E. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.12.001 · Cited by 13
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Béliard, S., Mourre, F., & Valéro, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06100-z · Cited by 10
Antilipidemic Drug Therapy Today and in the Future
Kramer, W. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_15 · Cited by 9
Kim, J. Y., Kim, N. H., Lee, J. Y., Kim, D., & Kim, S. G. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf053 · Cited by 10
Bazarbashi, N., & Miller, M. J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.006 · Cited by 10
Aterogénica, P. E. D. E. V. E. D. G. D. T. S. D. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.12.001 · Cited by 11
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 11
Kim, N. H., Lee, J., Chon, S., Yu, J. M., Jeong, I., Lim, S. K., Kim, W. J., Song, K., Cho, H., Yu, H. M., et al. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1995 · Cited by 7
Brea, Á., Pintó, X., Ascaso, J. F., Blasco, M., Díaz, Á., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Millán, J., & Pedro‐Botet, J. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.001 · Cited by 6
Combination lipid therapy in type 2 diabetes mellitus
Vergès, B. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.558503 · Cited by 7
Chen, Y., Zhao, S., & Ye, H. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1747416 · Cited by 8
Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki, K. C., & Dicklin, M. R. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000741 · Cited by 6
Morieri, M. L., Pipino, C., & Doria, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091402 · Cited by 7
Halcox, J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.16 · Cited by 7
Consensus statement on the management of dyslipidaemias in adults
Béliard, S., Bonnet, F., Bouhanick, B., Bruckert, É., Cariou, B., Charrière, S., Durlach, V., Moulin, P., Valéro, R., & Vergès, B. L. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.11.001 · Cited by 7
Yen, C., Fan, P., Lee, C., Chen, J., Chen, C., Tu, Y., Chu, P., Hsiao, C.-C., Chen, Y., & Chang, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1333553 · Cited by 6
Al-Zakwani, I. S., Almahmeed, W. A., Shehab, A. M., Arafah, M., Al-Hinai, A. T., Tamimi, O. A., Alawadhi, M., Herz, S. A., Anazi, F. A., Nemer, K. A., et al. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0160-6 · Cited by 5
Terapia con fibratos: uso racional del fenofibrato 2016. Resumen ejecutivo
Brea, Á., Millán, J., Ascaso, J. F., Blasco, M., Rodríguez, Á. D., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.06.001 · Cited by 5
Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States
Maki, K. C., Benes, L. B., & Dicklin, M. R. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_16 · Cited by 8
Brea, Á., Millán, J., Ascaso, J. F., Blasco, M., Díaz, A., Hernández‐Mijares, A., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2018.06.002 · Cited by 7
Farnier, M., Dong, Q., Shah, A. K., Johnson‐Levonas, A. O., & Brudi, P. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-212 · Cited by 7
Schwere Hypertriglyzeridämie: Diagnostik und neue Therapieprinzipien
Kassner, U., Dippel, M., & Steinhagen‐Thiessen, E. (2017) · Der Internist · doi:10.1007/s00108-017-0234-z · Cited by 10
Triglycerides and Atherosclerotic Cardiovascular Disease.
Puri, R., Mehta, V., Iyengar, S. S., Narasingan, S. N., Duell, P. B., Sattur, G. B., Vijayaraghavan, K., Mohan, J. C., Wangnoo, S. K., Dalal, J. J., et al. (2020) · PubMed · Cited by 4
Heterogeneity of diabetic dyslipidemia, data from the NHANES (2011–2016)
Li, Y.-S., Liu, J., Huang, N., Cui, H., & Li, J. (2024) · Medicine · doi:10.1097/md.0000000000037173 · Cited by 4
Metabolic and cardiovascular risk factor control in a diabetic cohort. Four-year results
Iglesias, O. L., Marcos, J. S., Cortés, V., Luque, A., Gaillemin, B. C., Delgado, A. V., Martínez, A. M., & López, J. L. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.02.004 · Cited by 4
Chan, D. C., Pang, J., & Watts, G. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_30-1 · Cited by 7
Triglycérides et risque cardiovasculaire
Valéro, R. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30041-0 · Cited by 6
Vaverková, H., & Karásek, D. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.004 · Cited by 5
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 5
Pedro‐Botet, J., Barrios, V., Sánchez‐Margalet, V., Tamargo, J. L., Arrieta, F., Gámez, J. M., Gimeno-Orna, J. A., Escobar, C., Gómez‐Doblas, J. J., & Pérez, A. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.03.004 · Cited by 5
Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia
Bhatia, V., Arora, P., Kaur, G., & Kaul, U. (2017) · Heart Research - Open Journal · doi:10.17140/hroj-4-135 · Cited by 3
Quelle place pour les fibrates après l‘étude ACCORD-Lipids ?
Vergès, B. L. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70303-0 · Cited by 3
Is triglyceride therapy worth the effort?
Miller, M. J. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.13157 · Cited by 4
Atherogenic Dyslipemia Working Group of the Spanish Society of Atherosclerosis and the European Expert Group (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.002 · Cited by 4
Atherogenic dyslipidaemia in type 2 diabetes mellitus: The PREDISAT study
Climent, E., Millán, J., Ascaso, J. F., Tembra, M. S., Morillas, C., Civeira, F., Bellón, J. M., Pedro‐Botet, J., & the Spanish Atherosclerosis Society Working Group on Atherogenic Dyslipidaemia (2023) · Lipids · doi:10.1002/lipd.12374 · Cited by 3
Farnier, M. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.37 · Cited by 3
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins
Anabtawi, A., Moriarty, P. M., & Miles, J. M. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0872-8 · Cited by 6
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Tratamiento combinado con fenofibrato. Eficacia
Brea, Á. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(12)70012-8 · Cited by 2
Evidence for use of fibrates in diabetic dyslipidemia: are we looking hard enough?
Munigoti, S. P., & Rees, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328342b0e9 · Cited by 2
Názara-Otero, C., Argüeso, R., Pedro‐Botet, J., Pintó, X., Millán, J., Seijo, M. P., Fernández, P. A., Ameneiros, M. E., del Alamo, A., Rodríguez, A., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2022.11.002 · Cited by 2
Lipid management in Type 2 diabetes: the case for combination therapy?
Saely, C. H., Drexel, V., Vonbank, A., & Drexel, H. (2011) · Therapy · doi:10.2217/thy.11.5 · Cited by 2
Self-citationMedication‐based versus target‐based lipid management
Fazio, S., & Shapiro, M. D. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12789 · Cited by 2
“Clinical trials of fibrates have, at best, provided hints that subgroups of patients with combined dyslipidemia may derive cardiovascular benefit beyond that produced by statin monotherapy, but most experts would agree that peculiarities in study design are the main reason why the results were not more obviously posit…”
ResultAssociation of Non-LDL Indices with Recurrent Stroke Risk while on Lipid-Modifying Therapy
Park, J., & Ovbiagele, B. I. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.49304 · Cited by 2
Fibrate Use in the United States and Canada
Tenenbaum, A. (2011) · JAMA · doi:10.1001/jama.2011.945 · Cited by 2
Athyros, V. G., Doumas, M. N., & Karagiannis, A. I. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.02.022 · Cited by 2
Small Dense Low-Density Lipoprotein: Biomarker or Potential Drug Target?
Samanta, B. (2019) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0039-1697239 · Cited by 1
Metadata
- Authors
- Saely, C. H., Rein, P., & Drexel, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-08-12
- Volume
- 363
- Issue
- 7
- Pages
- 692-695
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1519335354
- Cited by
- 245
- References
- 12
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 12 · 2022: 10 · 2021: 6 · 2020: 17 · 2019: 19 · 2018: 17 · 2017: 23 · 2016: 28 · 2015: 20 · 2014: 14 · 2013: 21 · 2012: 17
- FWCI
- 20.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, lipid-lowering therapy, hypertriglyceridemia, dyslipidemia, cardiovascular risk
- MeSH terms
- Hypolipidemic Agents, Coronary Artery Disease, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Male, Fenofibrate, Risk, Triglycerides, Hypertriglyceridemia, Proportional Hazards Models, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.